April 06, 2024

All-Purpose Drugs: GLP-1s Offer Hope in Neurodegenerative Disease

Glucagon-like peptide-1 receptor agonists (GLP-1) have emerged as a beacon of hope for the millions of people worldwide living with obesity and type 2 diabetes (T2D). These serious diseases have become global public health issues in the last three decades – the result of urbanization, sedentary lifestyle, and increased consumption of high-calorie processed foods. Obesity… [Read More]
April 05, 2024

PRISM Market Moves on Friday: Kura Sushi and Krispy Kreme Surge; Tesla and Plug Power Fall

US equities are trading higher on Friday afternoon after stocks came under pressure on Thursday. Big tech is mostly higher and other outperformers include semis/semicaps, software, life sciences, railways, building materials, P&C insurers, machinery, and entertainment. Pharma, solar, regional banks, diversified chemicals, packaging, consumer staples, and airlines are lagging Treasuries are notably weaker, the Dollar… [Read More]
April 05, 2024

ZyVersa Highlights Data Demonstrating Inflammasome Inhibition Slows Progress of Diabetic Atherosclerosis

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) has highlighted data published in a peer-reviewed journal  that demonstrates that NLRP3 inhibition results in improved glucose tolerance and markedly smaller and more stable atherosclerotic lesions in a diabetic mouse model. ZyVersa is developing IC 100, a monoclonal antibody targeting inflammasome specks including NLRP3, to block damaging inflammation that leads… [Read More]
April 05, 2024

PolTREG Identifies Key Biomarker for Efficacy in Pediatric Type 1 Diabetes

Polish biotechnology company, PolTREG S.A. (Warsaw Stock Exchange: PTG)  has published data in International Immunopharmacology which suggest that PD-1+ T-cells are a dependable biomarker for efficacy in pediatric early-onset Type-1 diabetes (T1D) patients, who had been successfully treated with PTG-007 Treg cell therapy, the company’s lead asset. The results are from a two year follow-up… [Read More]
April 05, 2024

DiogenX Attracts Significant Funding for Disease-Modifying T1D Therapy

Privately-held European biotechnology company, DiogenX, continues to attract significant funding from sophisticated healthcare investors for its lead program, a first-in-class recombinant protein that aims at replicating insulin-producing beta cells in the pancreas. This novel approach has the potential to offer a disease-modifying therapy for type 1 diabetes, a chronic and life-threatening condition that affects millions… [Read More]
April 05, 2024

Biomea Fusion Pursues Unparalleled Opportunity to Address Root Cause of Diabetes

Biopharmaceutical company, Biomea Fusion (Nasdaq: BMEA) has reported positive initial response data from two type 1 diabetes patients treated with BMF-219 in the company’s ongoing Phase 2 clinical trial. Both patients showed improvement in measures of beta-cell function after four weeks of dosing with BMF-219. More than 37 million people in the US have diabetes,… [Read More]
April 04, 2024

PRISM Market Moves on Thursday: STAAR Surgical Shines; Paramount and Hertz Tumble

US equities are trading higher on Thursday afternoon, following a strong finish Wednesday. Big tech is performing well, along with airlines, machinery, REITs, banks, software, and asset managers. It is a tougher day for retail, casual diners, hospitals, large-cap pharma, oil services, and grocers. Treasuries are mixed, the Dollar index is down (0.2%), Gold is… [Read More]